A distinct innate immune signature marks progression from mild to severe COVID-19

Chevrier, Stéphane; Zurbuchen, Yves; Cervia, Carlo; Adamo, Sarah; Raeber, Miro E; de Souza, Natalie; Sivapatham, Sujana; Jacobs, Andrea; Bachli, Esther; Rudiger, Alain; Stüssi-Helbling, Melina; Huber, Lars C; Schaer, Dominik J; Nilsson, Jakob; Boyman, Onur; Bodenmiller, Bernd

doi:10.1016/j.xcrm.2020.100166

Citations

Citation copied

Chevrier, S., Zurbuchen, Y., Cervia, C., Adamo, S., Raeber, M. E., de Souza, N., Sivapatham, S., Jacobs, A., Bachli, E., Rudiger, A., Stüssi-Helbling, M., Huber, L. C., Schaer, D. J., Nilsson, J., Boyman, O., & Bodenmiller, B. (2021). A distinct innate immune signature marks progression from mild to severe COVID-19. Cell Reports Medicine, 2(1), 100166. https://doi.org/10.1016/j.xcrm.2020.100166

Abstract

Coronavirus disease 2019 (COVID-19) manifests with a range of severities, but immune signatures of mild and severe disease are still not fully understood. Here, we use mass cytometry and targeted proteomics to profile the innate immune response of patients with mild or severe COVID-19 and of healthy individuals. Sampling at different stages allows us to reconstruct a pseudo-temporal trajectory of the innate response. A surge of CD169+ monocytes associated with an IFN-γ+MCP-2+ signature rapidly follows symptom onset. At later stages, w